Ozempic for Adults 65 and Older: Managing the Transition to Adult Care

Why Geriatric Patients Are a Distinct Population for Semaglutide

Older adults are not simply older versions of younger patients. Body composition, renal clearance, gastric motility, and polypharmacy burden all shift in ways that change how semaglutide behaves clinically. A 72-year-old with stage 3a CKD, metformin, lisinopril, and a loop diuretic is a materially different prescribing context than a 45-year-old with diet-controlled diabetes.

The FDA label for Ozempic states that no dose adjustment is required based on age alone, but it also notes that clinical trials enrolled limited numbers of patients aged 75 and older, meaning real-world geriatric experience must supplement trial data [1]. Prescribers and care coordinators managing transitions between primary care, endocrinology, geriatrics, and telehealth platforms need a structured framework for this group.

Physiological Changes That Alter Drug Response

Gastric emptying slows with age independent of semaglutide. Adding a GLP-1 receptor agonist that further delays gastric emptying can produce nausea and vomiting intense enough to cause rapid dehydration in a frail older patient. In the SUSTAIN 6 trial (N=3,297, mean age 64.6), serious adverse events related to gastrointestinal symptoms were numerically more frequent in participants over 65 [2].

Renal function also changes. The FDA prescribing information notes that postmarketing surveillance identified cases of acute kidney injury, some requiring dialysis, in patients who experienced GI-driven volume depletion [1]. This risk is amplified in geriatric patients who already have reduced renal reserve.

Lean Mass and Sarcopenia

Weight loss with semaglutide is approximately 30 to 40% lean mass and 60 to 70% fat mass in clinical trial populations. For a 68-year-old woman already at sarcopenic thresholds, losing 4 kg of lean mass over 18 months may worsen functional capacity more than it improves metabolic markers. The American Geriatrics Society recommends that weight-loss interventions in older adults always include resistance exercise and protein targets of at least 1.2 g per kg body weight per day [3].

Clinicians should assess baseline gait speed, grip strength, and SARC-F score before starting semaglutide in any patient aged 70 or older. A SARC-F score of 4 or higher warrants a formal physical therapy referral concurrent with GLP-1 initiation, not afterward.

Evidence Base: What Trials Tell Us About Older Adults on Semaglutide

SUSTAIN Trials in Older Subgroups

The SUSTAIN program enrolled patients with type 2 diabetes across eight phase 3 trials. Pooled subgroup analyses of participants aged 65 and older consistently show that semaglutide achieves HbA1c reductions of 1.1 to 1.6 percentage points from baseline, comparable to younger cohorts [4]. Hypoglycemia rates were low when semaglutide was used as monotherapy or with metformin, but rose substantially when combined with sulfonylureas. In SUSTAIN 2 (N=1,231, 52 weeks), hypoglycemia requiring assistance occurred in 1.6% of the semaglutide 1.0 mg arm versus 0.2% in the sitagliptin arm across all ages [4].

SELECT Trial and Cardiovascular Outcomes

The SELECT trial (N=17,604, median follow-up 34.2 months) enrolled adults with overweight or obesity and established cardiovascular disease but without diabetes [5]. Semaglutide 2.4 mg weekly reduced the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 20% (HR 0.80, 95% CI 0.72 to 0.90, P<0.001). Approximately 27% of SELECT participants were aged 65 or older. In the pre-specified age subgroup, the benefit was directionally consistent, though the hazard ratio in older adults trended slightly toward 0.83 compared to 0.78 in younger participants [5].

The FDA's 2023 label update for Wegovy (semaglutide 2.4 mg) incorporated SELECT data, but Ozempic's cardiovascular labeling derives primarily from SUSTAIN 6, where semaglutide 0.5 mg and 1.0 mg reduced the same three-point MACE composite by 26% (HR 0.74, 95% CI 0.58 to 0.95) in patients with type 2 diabetes and high cardiovascular risk [2].

SUSTAIN 6 Renal Outcomes

In SUSTAIN 6, new or worsening nephropathy occurred in 3.8% of semaglutide patients versus 6.1% of placebo patients, a 36% relative risk reduction [2]. This finding is particularly relevant for geriatric patients with early CKD, who make up a large share of the over-65 type 2 diabetes population. Prescribers managing patients with eGFR between 30 and 60 mL per min per 1.73 m² should note that no dose reduction is required by label, but volume status and concurrent nephrotoxin use deserve explicit review at every visit.

Transitional Care: The Highest-Risk Moment for Geriatric Patients on Semaglutide

Care transitions introduce medication errors. A geriatric patient discharged from hospital to skilled nursing facility (SNF), or transferred from an endocrinologist to a telehealth platform, or handed off between PCP and geriatrician, faces real risk if semaglutide management is not explicitly communicated.

Medication Reconciliation Priorities

The Joint Commission's National Patient Safety Goal 03.06.01 requires complete medication reconciliation at every transition of care [6]. For semaglutide specifically, the reconciliation checklist should confirm:

• Current dose and last injection date (semaglutide has a 7-day dosing interval and a half-life of approximately one week)
• Whether insulin or sulfonylurea co-prescriptions have been adjusted downward to account for the HbA1c-lowering effect of semaglutide
• Oral medication absorption timing (semaglutide's gastric-emptying delay can reduce peak concentrations of oral drugs taken within two hours of injection)
• Hydration and oral intake status, especially post-hospitalization

The ADA's Standards of Medical Care in Diabetes (2024) explicitly recommends that care transitions for older adults with diabetes include a dedicated pharmacist or diabetes care and education specialist review within 72 hours of discharge [7].

Telehealth-to-In-Person Transitions

Geriatric patients initiating semaglutide via telehealth and transitioning to in-person care present a specific documentation gap. Telehealth records may not capture objective physical examination findings: weight, blood pressure, signs of dehydration, or gait assessment. When a geriatric patient transfers from a telehealth prescriber to an in-person primary care physician or geriatrician, the receiving clinician should obtain a complete metabolic panel, eGFR, and weight within the first 30 days.

Hospital Discharge to SNF or Home Health

Semaglutide's once-weekly subcutaneous injection requires that SNF staff or home health aides are trained on pen device use. The FDA prescribing information specifies that Ozempic should be injected in the abdomen, thigh, or upper arm, and that the injection site should be rotated [1]. Older patients with reduced subcutaneous fat or skin changes may require nurse-administered doses rather than self-injection.

Appetite suppression persists for the full week after each dose. This is clinically significant at SNFs, where protein-calorie malnutrition is already prevalent. The CMS Minimum Data Set assessment for nutritional status should be updated to reflect GLP-1-induced appetite suppression as a contributing factor if a patient's dietary intake falls below 75% of needs.

Dose Escalation Strategy in Adults 65 and Older

The standard Ozempic dose escalation schedule starts at 0.25 mg weekly for four weeks, then 0.5 mg as the maintenance dose, with optional increase to 1.0 mg after at least four weeks if additional glycemic control is needed, and 2.0 mg as a further option [1]. In geriatric patients, prescribers at HealthRX follow a modified schedule: hold each dose level for eight weeks rather than four before escalating. This slower titration reduces the incidence of GI adverse events that drive dehydration and AKI.

Dose Holds During Acute Illness

Older adults are disproportionately affected by acute illnesses that cause volume depletion: gastroenteritis, pneumonia, urinary tract infections. The standard sick-day rule for GLP-1 receptor agonists is to hold the dose if the patient cannot maintain oral hydration. Caregivers and SNF staff should have written instructions covering this scenario. Restarting semaglutide after a hold longer than two weeks may require reverting to a lower dose tier to avoid recurrence of GI intolerance.

Monitoring Parameters

At minimum, geriatric patients on semaglutide should have the following monitored every three months during the first year:

• HbA1c
• Basic metabolic panel including eGFR and potassium
• Body weight with documentation of whether loss is from fat mass versus concerning lean-mass decline
• Functional assessment (gait speed or Timed Up-and-Go test)
• Review of insulin and sulfonylurea doses for downward adjustment

Drug Interactions Especially Relevant in Older Adults

Oral Hypoglycemics and Insulin

Semaglutide adds to the glucose-lowering effect of insulin and sulfonylureas. The ADA recommends reducing insulin dose by 10 to 20% when initiating a GLP-1 receptor agonist to reduce hypoglycemia risk [7]. In geriatric patients, hypoglycemia carries outsized risk because it is a leading cause of falls and fall-related hip fractures. The American Geriatrics Society Beers Criteria explicitly lists sulfonylureas as potentially inappropriate in older adults due to this risk [8].

Anticoagulants

Semaglutide's delay of gastric emptying may alter the absorption profile of warfarin. Post-marketing case reports have noted INR fluctuations in patients initiating GLP-1 agonists while on warfarin. The FDA label recommends monitoring patients on warfarin when starting or changing the dose of semaglutide [1]. Direct oral anticoagulants (DOACs) have fixed pharmacokinetics less dependent on gastric pH, but reduced renal clearance in patients with CKD may still require INR or drug-level monitoring when volume status changes.

Thyroid Function and Monitoring

The Ozempic prescribing information carries a boxed warning for thyroid C-cell tumors based on rodent studies. While human relevance has not been established, a personal or family history of medullary thyroid carcinoma or MEN2 remains a contraindication [1]. In older adults, thyroid disease is common (subclinical hypothyroidism affects up to 15% of women over 70 [9]), and TSH should be checked before initiation and annually thereafter, both to rule out contraindications and because hypothyroidism independently causes dyslipidemia, weight gain, and fatigue that can confound the assessment of semaglutide's effects.

Patient Education and Caregiver Communication

Injection Training for Older Adults

The Ozempic FlexTouch pen requires a button-press force of approximately 8.5 Newtons. Studies of arthritis in older adults show that a meaningful proportion of patients aged 70 and older cannot reliably generate this force [10]. Before prescribing self-injection, assess grip strength and finger dexterity. Autoinjector training with occupational therapy referral should be standard practice, not an afterthought.

Nutritional Counseling

The appetite suppression from semaglutide in geriatric patients can be profound. A 68-year-old patient who was struggling to eat 1,600 calories per day before starting semaglutide may drop to 1,100 calories, insufficient for muscle maintenance. Registered dietitian referral is not optional in this population. The goal is not simply caloric intake but protein density: at least 30 grams of high-quality protein per meal, three times per day.

As the Endocrine Society's 2023 Pharmacological Management of Obesity guideline states: "Anti-obesity medications should always be used as adjuncts to lifestyle intervention, and in older adults, lifestyle intervention must explicitly address the risk of muscle and bone loss." [11]

Family and Caregiver Involvement

Many geriatric patients have family members or professional caregivers involved in medication management. Written sick-day instructions, a list of symptoms warranting dose hold (persistent vomiting, diarrhea lasting more than 24 hours, inability to drink fluids, signs of dehydration), and an emergency contact protocol for the prescribing clinician should be provided at every visit.

When to Reconsider Semaglutide in an Older Patient

Not every geriatric patient is an appropriate candidate. Patients with BMI <25 and well-controlled diabetes who are already at sarcopenic weight may experience net harm from additional weight loss. Patients with advanced CKD (eGFR <15), active gastroparesis, a history of pancreatitis, or MEN2 should not receive semaglutide regardless of age [1].

The decision to continue semaglutide long-term in a geriatric patient who has achieved glycemic goals and who is experiencing continued weight loss from lean mass should prompt a frank discussion about whether the cardiovascular benefits outweigh the functional risks. Weight stabilization, rather than ongoing loss, may be the goal after the first 12 to 18 months of therapy.

The 2024 ADA Standards of Medical Care note that in older adults with diabetes, "less stringent glycemic goals (HbA1c <8.0% or even <8.5% for those with complex health status) may be appropriate to reduce hypoglycemia risk and treatment burden." [7] Reaching HbA1c below 7.0% with semaglutide in a frail 80-year-old increases hypoglycemia risk without clear mortality benefit.